Discovery of Pyrazolo[3,4-d]pyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological Evaluation.
Source check: Source checked. Not independent scientific confirmation.
Finding: A scaffold-design workflow incorporating a deep generative model, kinase screening and docking produced compound 2, with DDR1 IC50 10.6 ± 1.9 nM and selectivity tested against 430 kinases. Cell and mouse-colitis results are preclinical; sample sizes and comparators were not assessed from the abstract.
Technology: Deep generative molecular model
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- The publisher abstract identifies a deep generative model within a scaffold-design workflow with kinase selectivity screening and docking; its specific operation was not assessable from the abstract.
- Test and result
- The publisher abstract reports DDR1 IC50 10.6 ± 1.9 nM, selectivity testing against 430 kinases, cell cytokine/autophosphorylation assays and a DSS-induced mouse colitis model. Sample sizes and comparator details were not available in the reviewed abstract.
- Limitation / still unknown
- Only the publisher abstract and metadata were reviewed. Animal sample size, comparator regimen, detailed assay design and the generator's specific operation were not assessed; mouse results do not establish clinical efficacy.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.1021/acs.jmedchem.1c01205
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 18 Nov 2026. Review scope: Indexed primary ACS abstract, supporting-information inventory and online/issue metadata; complete article body not reviewed..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.